Lyra Therapeutics is developing a drug-eluting elastomeric matrix for chronic rhinosinusitis (“CRS”) that can be placed in the sinus cavity by an ENT physician during an office visit. The product ...
Lyra Therapeutics has had a successful few months since its IPO, with updates on its phase 2 studies and progress towards phase 3 data. The company's proprietary XTreo platform uses a biocompatible ...
LianBio has licensed exclusive rights to Lyra Therapeutics’ nasally administered treatment for chronic rhinosinusitis (CRS) in China and other Asian markets. Lyra is receiving $12 million upfront in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results